Genomic Health colon cancer test wins Medicare coverage

Medicare will cover Genomic Health Inc.’s Oncotype DX colon cancer recurrence test.
The Redwood City medical diagnostics company (NASDAQ: GHDX) said Friday that Columbia, S.C.-based Palmetto GBA, which administers Medicare health insurance for the Centers for Medicare & Medicaid Services, established a formal coverage policy for all Medicare patients with stage II colon cancer.
The coverage is effective for claims as of Sept. 18.